Overview

We are a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. Our second product candidate, GFH009, is a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor licensed from GenFleet Therapeutics, which we hold the exclusive rights to for further development and commercialization of the asset across all therapeutic and diagnostic uses outside of greater China. GPS and GFH009 have potential as monotherapies, or in combination with other therapies, to address a broad spectrum of hematologic malignancies and solid tumor indications.